News
![Teva Pharmaceutical Industries Ltd. Slashes Full-Year Outlook After Disappointing Second Quarter](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Teva Pharmaceutical Industries Ltd. Slashes Full-Year Outlook After Disappointing Second Quarter
Buying the Actavis Generics business from Allergan (NYSE: AGN) made the difference for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) when it reported first-quarter results in May. That deal boosted
![Globus Medical Enjoys Another Solid Quarter Thanks to International Sales Growth](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Globus Medical Enjoys Another Solid Quarter Thanks to International Sales Growth
So far, 2017 is shaping up to be the best year for Globus Medical (NYSE: GMED) shareholders in quite a while. The musculoskeletal implant manufacturer posted great numbers for the first quarter
![Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late
![ResMed Tops Expectations but Falls Anyway](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
ResMed Tops Expectations but Falls Anyway
Medical-device maker ResMed (NYSE: RMD) reported its fiscal fourth-quarter results after the market closed on Tuesday, Aug. 1. The continuous positive airway pressure (CPAP) pioneer reported modest
![Restriktive und Expansive Geldpolitik – Beispiel Japan](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Restriktive und Expansive Geldpolitik – Beispiel Japan
Restriktive und Expansive Geldpolitik
Zuerst muss ich ein wenig ausholen. Nach der Finanzkrise im Jahr 2008 hat die amerikanische Notenbank FED ein großes Anleihekaufprogramm gestartet, um denn....
![10 Reasons Illumina's Momentum Is Just Cranking Up](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings
![IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
IDEXX Laboratories (NASDAQ: IDXX) reported solid revenue growth with operating income and earnings growing even faster allowing the animal diagnostic company to raise 2017 guidance.But investors
![Illumina Soars After Crushing Expectations for Q2](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3%
![3 Companies Building the World of Tomorrow](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
3 Companies Building the World of Tomorrow
It's always intriguing to think about what new technologies the future will bring. But what you might not realize is that many of the building blocks of tomorrow are already in place. And lucky for
![Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few
![President Trump's Breaking of This 148-Year Streak Won't Slow This Trend One Bit](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
President Trump's Breaking of This 148-Year Streak Won't Slow This Trend One Bit
When Donald Trump entered the Oval Office, we knew things would be a bit different. After all, he's the first president ever to not have any military or political experience, and he's just the second
![McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement
Republicans have been fighting to repeal and replace the Affordable Care Act since it was passed by Democrats in 2010. After winning Congress and the White House last November, many republicans
![Here's Why Align Technology Marched Higher Again Today](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Here's Why Align Technology Marched Higher Again Today
Shares of Align Technology, Inc. (NASDAQ: ALGN), an orthodontic-device company, rose about 10% during Friday's session. Record results released after the bell on Thursday should keep investors smiling
![Why Mednax Tumbled 12% Today Despite Higher Sales](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Why Mednax Tumbled 12% Today Despite Higher Sales
Despite reporting 9.2% year-over-year sales growth, a sharp decline in profitability sent shares in Mednax (NYSE: MD) lower Friday. Shares were down 11.9% at noon EDT. Mednax is a large provider of
![Abiomed, Inc. Starts Its Fiscal Year on a High Note](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Abiomed, Inc. Starts Its Fiscal Year on a High Note
Abiomed (NASDAQ: ABMD), a medical-device company focused on minimally invasive heart pumps, reported its fiscal first-quarter earnings on Thursday, July 27. The company's results proved yet again that
![Align Technology Again Makes Investors Smile With a Record Second Quarter](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Align Technology Again Makes Investors Smile With a Record Second Quarter
Align Technology's (NASDAQ: ALGN) first quarter was one for the record books. On Thursday, Align announced its second-quarter results. The orthodontic-device maker reported all-time high revenue
![Executive Changes Hit NuVasive Hard](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Executive Changes Hit NuVasive Hard
Advances in medical science have had a dramatic impact on the quality of care that patients receive. In the area of spinal surgery, NuVasive (NASDAQ: NUVA) has made a lot of headway with its minimally
![Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
![Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth
Baxter (NYSE: BAX) kept with its trend in the second quarter of marginal revenue growth, but included a substantial improvement in spending, resulting in an increase in earnings that once again beat
![Natus Medical Inc Looks to Turn Things Around](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Natus Medical Inc Looks to Turn Things Around
Natus Medical (NASDAQ: BABY) continued the trend from the first quarter of the year: Revenue came in substantially higher in the second quarter, due to the addition of revenue from the company's
![Why Community Health Shares Are Crashing 15.6% Today](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Why Community Health Shares Are Crashing 15.6% Today
Only days after competitor HCA reported disappointing second-quarter results, Community Health Systems (NYSE: CYH) provided a peek at its own second-quarter performance. Unfortunately, the preliminary
![Why Amedisys Is Crashing 14.3% Today](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Why Amedisys Is Crashing 14.3% Today
After the Centers for Medicare and Medicaid Services (CMS) said it may reduce reimbursement for home healthcare by 0.4% in 2018, shares in Amedisys Inc. (NASDAQ: AMED) are losing 14.3% of their value
![Intuitive Surgical, Inc. Slow Earnings Growth Masks Deeper Strength](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Intuitive Surgical, Inc. Slow Earnings Growth Masks Deeper Strength
One look at the bottom line from Intuitive Surgical's (NASDAQ: ISRG) earnings release and you might think that the company had hit a speed bump. With the stock trading at 42 times trailing (non-GAAP)
![UnitedHealth Group's Sales Surge Above $50 Billion, Despite Exiting Obamacare](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
UnitedHealth Group's Sales Surge Above $50 Billion, Despite Exiting Obamacare
UnitedHealth Group's (NYSE: UNH) decision to stop selling Obamacare plans this year hasn't dented its momentum. The nation's biggest health insurer reported sales of $50 billion in the second quarter
![UnitedHealth Sees a Healthier Future](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
UnitedHealth Sees a Healthier Future
Healthcare is front and center in Washington once more, and lawmakers have made little progress toward making anticipated changes on the insurance front. In the absence of more reform efforts, health